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Amanda R. Ricchio, BA,1 Julia A. Schweiger, CCRC,1 Robert L. Findling, MD, MBA,4
Denise Wilfley, PhD,1,5,6 and John W. Newcomer, MD1,7
Abstract
Objectives: The purpose of this pilot study was to evaluate changes in adiposity, carotid intima media thickness (CIMT), and
hepatic fat content measured via magnetic resonance imaging-estimated hepatic proton density fat fraction (PDFF) in
antipsychotic (AP)-treated youth versus nonpsychiatric (NP) participants during participation in a 16-week behavioral weight
loss (BWL) intervention.
Subjects/Methods: Overweight/obese AP-treated youth (n = 26) were randomized 2:1 to weekly treatment versus re-
commended care (RC) over 16 weeks. NP controls (n = 21) were assigned to weekly treatment. Dual-energy X-ray ab-
sorptiometry (DEXA)-measured adiposity, CIMT, and PDFF were measured at baseline and 16 weeks. Analyses assessed
group differences in the effect of BWL on adiposity, CIMT, and PDFF.
Results: BWL was well tolerated in both AP-treated and NP groups. DEXA-measured fat decreased significantly in the NP
group (F[1,16] = 11.81, p = 0.003), with modest improvements in adiposity and hepatic fat in the AP-treated group, while an
increase in adiposity was observed in the RC group. Significant differences in endpoint DEXA total fat (F[2,34] = 4.81,
p = 0.01) and PDFF (F[2,30] = 3.60, p = 0.04) occurred across treatment groups, explained by larger improvements in NP
versus RC youth in DEXA total fat ( p = 0.03) and PDFF ( p = 0.04).
Conclusions: Intensive, family-based BWL treatment can improve whole-body adiposity and liver fat in obese youth, with
decreases or attenuation of additional fat gain observed in AP-treated youth.
Keywords: obesity, antipsychotic, weight loss, child psychiatry
Introduction
Persons with major mental illnesses, including childhood-onset illnesses such as attention-deficit/hyperactivity disorder
(ADHD), lose a mean of 15–20 years of potential life expectancy
compared with the general population, primarily due to chronic
obesity-related conditions (Colton and Manderscheid 2006; Nor-
dentoft et al. 2013). Populations at increased risk for developing
obesity include children and adolescents with common conditions
such as ADHD and autism spectrum disorders (ASDs), where rates
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of overweight and obesity are higher than in the general population
(Hill et al. 2015; Cortese et al. 2016).
Childhood- versus adult-onset obesity-related conditions in gen-
eral lead to early onset of costly medical conditions such as car-
diovascular disease (Morrison et al. 2007). Indeed, health care
utilization in adults with ASD and ADHD is higher than in the
general population, primarily related to treatment for chronic obesity-
related illnesses such as diabetes and hyperlipidemia (Birnbaum et al.
2005; Ousseny et al. 2018). Thus, obesity prevention and treat-
ment in this population are critical to preserving longevity, as well
as for health care cost-containment.
Higher chronic disease burden in mentally ill individuals is
multifactorial, associated with patient-, provider-, and system-level
variables (Walker et al. 2015). As public health interest in managing
cardiometabolic risk in this population grows, attention has begun
to shift toward prevention in the particularly high-risk population
of children with mental health conditions who receive early exposure
to obesogenic psychotropic drugs, such as antipsychotic medica-
tions. In the early 1990s–2000s, a significant increase in the rate of
antipsychotic prescriptions in youth was observed (Olfson et al.
2006), primarily for off-label treatment of irritability and aggression
associated with disruptive behavior disorders (DBDs) or ADHD
(Connor et al. 2006; Crystal et al. 2009; Pathak et al. 2010).
While antipsychotic treatment can significantly improve irrita-
bility and aggression in autism and other pediatric-onset disorders,
treatment-related effects on adiposity, insulin sensitivity, and lipid
profiles have been described (Calarge et al. 2009; Correll et al.
2009) and associated with adverse cardiometabolic outcomes
(McIntyre and Jerrell 2008; Morrato et al. 2010). In previously
antipsychotic naive children assigned to 12 weeks of randomized
antipsychotic treatment, gold standard measures have been used
to identify rapid-onset adverse treatment effects on whole-body
and abdominal adiposity as well as tissue-specific insulin sensi-
tivity (Nicol et al. 2018). In that study, combined rates of over-
weight and obesity rose from a general population norm of *30%
to 47% in just 12 weeks.
Although differential weight gain effects among atypical agents
have been observed (Newcomer 2007; Yoon et al. 2016), this dif-
ference does not appear to have a significant effect when compared
across treatment studies—particularly in antipsychotic naive
younger patients (Zhang et al. 2016). Although a small amount of
metabolic effect may be weight independent (Birkenaes et al.
2008), the level of adiposity achieved during antipsychotic
treatment, rather than the antipsychotic treatment itself, appears to
be prominently correlated with direct measures of metabolic risk
such as intrahepatic fat content (Nicol et al. 2015). Thus, ad-
dressing excess adiposity in this population is a primary risk
prevention target.
Behavioral weight loss (BWL) interventions have been suc-
cessfully used in adult mentally ill populations (Daumit et al. 2013;
Erickson et al. 2016), and are considered first-line treatment for
pediatric obesity (Quattrin and Wilfley 2017). However, unadapted
BWL interventions may have attenuated efficacy in psychiatrically
ill youth (Detke et al. 2016; Nicol et al. 2016b). Intensive family-
based weight management interventions have received significant
study in both pediatric obesity (Wilfley et al. 2007, 2017) and eating
disorders (Le Grange et al. 2016), but have received no study in
antipsychotic (AP)-treated youth.
We therefore aimed to pilot-test a family-based BWL intervention—
initially developed for use in nonpsychiatric (NP) youth (Wilfley
et al. 2007)—in mentally ill AP-treated youth, using validated
biomarkers of cardiometabolic disease risk, including dual-energy
X-ray absorptiometry (DEXA)-measured body fat, hepatic triglyc-
eride content using magnetic resonance (MR) imaging-estimated
proton density fat fraction (PDFF), and carotid intima media thick-
ness (CIMT), evaluated as an early marker of cardiovascular disease
risk in obese adolescents (Oren et al. 2003) and in youth with high-
risk conditions such as hypertension (Baroncini et al. 2017). We
hypothesized beneficial treatment-related changes in adiposity
and other biomarkers of risk with BWL treatment compared with a
recommended care (RC) health education control condition.
Materials/Subjects and Methods
Youth with overweight and obesity (body mass index [BMI]
percentile of 85–94 and ‡95, respectively), ages 6–18, were as-
signed to interventions as follows: AP-treated youth were ran-
domized 2:1 to weekly 16-week BWL or to the RC control
condition consisting of 4 once-per-month health education ses-
sions: NP participants received the 16-week BWL. AP-treated
participants had documented clinically significant weight gain
(e.g., weight gain over at least 6 months of antipsychotic treatment
that exceeds the expected 5–6 lbs typically experienced in 1 year
during peak adolescent growth) (Tanner 1989; Rogol et al. 2000),
and documented psychiatric stability before enrollment. Active
suicidality and estimated or documented intelligent quotient <70,
treatment with weight loss agents [other than stable, concurrent
stimulant medication at <1 mg/(kg$d) equivalent of methylpheni-
date], or prior diagnosis of an eating disorder was exclusionary.
Overweight or obese NP youth were recruited from primary care
offices in the area. Eligibility based on height, weight, and BMI
percentile was confirmed with medical records. NP participants
could not be taking psychotropic medications or medications as-
sociated with weight loss. An adult guardian/primary caregiver
provided written consent, and participants provided written assent
for study participation. This study was conducted between July
2011 and March 2017 at Washington University School of Medi-
cine in St. Louis, MO. The Washington University Institutional
Review Board approved this study.
Study assessments
Consensus diagnoses were determined by review of medical
records and the semistructured Mini International Neuropsychiatric
Interview for Children (MINI-Kid). The Aberrant Behavior
Checklist (ABC) (Aman and Singh 1994) was used to assess irri-
tability and aggression, symptoms commonly treated with anti-
psychotic medications.
DEXA-measured whole-body total (kg) and percent fat mass,
as well as whole-body lean (kg) mass, was measured with a Delphi
W densitometer (Hologic, Waltham, MA). PDFF was determined
by proton MR spectroscopy using a 1.5T scanner (MAGNETOM
Sonata; Siemens, Erlangen, Germany). CIMT was measured by
9- to 13-MHz B-mode carotid artery ultrasonography (Sequoia;
Acuson-Siemens, Mountain View, CA). A single sonographer
acquired B-mode images of carotid arteries in the longitudinal
axis bilaterally. A 1 cm region of the common carotid artery
proximal to the bifurcation was identified and exported for off-
line analysis with ProSolv software (FUJIFILM Medical Sys-
tems USA, Stamford, CT). CIMT measures were obtained by
taking the average of far-wall intima media thickness from both
left and right common carotid arteries. Each site represents the
average of three measures of the maximum CIMT, obtained by
two separate blinded raters. The interobserver intraclass corre-
lation coefficient was 0.70.
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Height and weight at baseline and 16 weeks used in primary
analyses were performed on a calibrated, wall-mounted stadi-
ometer (Seca 240) and scale (Seca 684), respectively, by a
trained research nurse. Fasting plasma lipids (total cholesterol,
low-density lipoprotein cholesterol, high-density lipoprotein
cholesterol, and triglyceride) and glucose were also obtained at
baseline and 16 weeks. Weekly treatment weights were measured
on a digital office-based scale (Health o meter; Sunbeam Products,
Inc., Boca Raton, FL, 2010) to guide content of treatment sessions
and to track progress.
Physical activity was estimated using parent or adult caregiver
report of metabolic equivalent of task minutes per week using the
International Physical Activity Questionnaire (IPAQ) (Hagstromer
et al. 2008) at baseline and 16 weeks. Fidelity to BWL and RC
treatment protocols was assessed via weekly interventionist self-
report, using a measure developed for other pediatric BWL studies
conducted by our group (TODAY Study Group 2010). Fidelity was
also monitored in weekly team supervision sessions lead by the
principal investigator (PI), incorporating analysis of video recorded
treatment sessions. Treatment adherence was measured by in-
person session attendance and interventionist assessment of
homework completion and quality by a scale used in previous
weight loss studies (TODAY Study Group 2010). See Supple-
mentary Data for additional details on study assessments and
procedures.
Randomization and treatment description
Randomization was generated in blocks of 10 and implemented
by the study coordinator, with open-label treatment assignment.
Group composition was monitored for gender, ethnicity, race,
and age.
Family-based social facilitation treatment is a previously es-
tablished BWL based on the Traffic Light Plan (Epstein and Squires
1988), adjusted to a 16-week duration for use in this study. The
Stoplight Plan classifies both nutritional values of foods and
physical activity intensity as RED for ‘‘stop and think’’ to indicate
the least healthy options, YELLOW for ‘‘caution’’ to indicate
moderately healthy options, and GREEN for ‘‘go’’ to indicate the
healthiest options. Parents or adult guardians were required to
attend sessions, ensure study-related homework was completed,
and promote health behavior changes in the home, but were not
considered study participants.
The target weight loss goal range is 0.5–2 lbs/week, in line with
evidence-based childhood obesity treatment (Epstein et al. 2004)
and recommendations for healthy child development and weight
management (Barlow 2007; Rao 2008). Expected annual weight
gain during normal growth and development varies based on age and
gender, and can range from 2 to 3 lbs in pre- and postpubertal youth
to 8–12 lbs/year during prepubertal and pubertal growth stages, with
weight gain higher in prepubertal females than in males, and higher
weight gain in males during puberty (Tanner 1989; Rogol et al. 2000).
For individuals who are already high weight, the range of 0.5–2
lbs/week is a safe weight loss range for all ages and stages of growth.
Core components of effective BWL strategies were incorporated
within a socioecological framework (Wilfley et al. 2007), along
with other behaviors relevant to weight management (e.g., self-
monitoring of activity and food intake, sleep) (Nicol et al. 2016b).
Participants met with interventionists weekly to review goals and
homework, to problem solve and plan. Weights were measured at
each in-person session on an office-based scale so that participants
could track progress. While treatment adaptation was not the goal
of the present study (e.g., we did not aim to change the treatment
content or treatment targets), some simple modifications were made
to the method of treatment delivery to decrease cognitive load for
participants.
Self-monitoring was simplified to reduce cognitive load by using
a log with visual cues rather than written lists. Weekly eating and
activity goals were adjusted to meet families at their current level of
ability and readiness for change, with flexibility to repeat concepts
not mastered from previous sessions if needed. A weekly ‘‘taste
log’’ was used to encourage systematic exposures to new ‘‘Green’’
foods and reduce selectivity for ‘‘Red’’ foods. Adult caregivers were
required to supervise completion of treatment-related homework and
weekly parenting goals were set to facilitate uptake of new health
behaviors. Caregivers were encouraged to adopt health behaviors
identified in treatment sessions, but adult weight loss was not re-
quired or specifically tracked.
The RC condition consisted of monthly visits with a study in-
terventionist, and included education about energy balance using
the Stoplight Plan described above. Each monthly visit consisted of
a weigh-in and check-in regarding successes and challenges ex-
perienced in the prior month regarding efforts to decrease caloric
intake, increase fruit and vegetable consumption, and increase
healthy physical activity, followed by identification of target areas
for problem-solving. Self-monitoring and specific goal setting were
not part of the control condition.
Adverse event monitoring
All participants provided consent to share medical information
with their primary care providers (PCPs) and mental health providers
(when applicable). All PCPs provided written clearance for their
patients to participate in the intervention. Monitoring for develop-
ment of adverse events, including excessive weight loss, develop-
ment of acute suicidality, or exacerbation of psychiatric symptoms,
was conducted at each study visit and reported to the patient’s PCP or
mental health provider to determine the appropriateness of ongoing
study participation on a case-by-case basis. Laboratory, imaging, and
anthropomorphic study assessments conducted at baseline and 16
weeks were reviewed for abnormal results, which were reported to
the participant’s PCP for additional follow-up.
Analytic strategy
In the present study, we aimed to evaluate DEXA-measured total
fat, CIMT, and percent PDFF following 16 weeks of weekly,
family-based, weight loss treatment or monthly health education in
AP-treated youth, compared with NP youth also undergoing
weekly, family-based, weight loss treatment. Primary analyses for
each outcome were conducted using a modified intent-to-treat
analysis (IBM SPSS, Armonk, NY), including participants with
baseline and any subsequent measurements. Means and standard
deviations (SDs) were used to describe the center and spread of all
variables. The primary analytic model used analysis of covariance
to test the main effect of treatment group (independent, fixed three-
level factor) on week 16 values of each primary and secondary
outcome (dependent variables), using each outcome’s baseline
value as the covariate term. Gender, age (£12 years), and stimulant
treatment (Y/N) were individually introduced into the models to
determine any potential impact each variable had on the primary
finding, if any. In cases where a significant main effect of treatment
group was observed, post hoc pairwise comparisons were per-
formed to evaluate differences in the endpoint variable after ad-
justing for baseline. Exploratory analyses applied a marginal model
WEIGHT LOSS BIOMARKERS IN ANTIPSYCHOTIC-TREATED YOUTH 441
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with an unstructured variance/covariance matrix to evaluate for
main effects of treatment fidelity and adherence. Using a marginal
model, we evaluated the effects of time and treatment group on
fidelity and adherence separately. We then evaluated the main ef-
fect of time on change in DEXA fat, with fidelity and adherence
inserted separately as covariates. This final model was run with and
without treatment group inserted as a factor.
Results
Participant characteristics
Participant disposition is detailed in Figure 1. Fifty participants
were consented and enrolled in the study, with 47 receiving base-
line evaluations. The mean age in the pooled sample was 13.3 years
(SD = 2.43). The ratio of male:female participants was higher in the
AP-treated groups, reflecting the higher prevalence of ASD,
ADHD, and DBDs in boys (Merikangas et al. 2010). Groups were
otherwise balanced on baseline characteristics (Table 1).
AP-treated groups were diagnostically heterogeneous, with the
mean number of psychiatric diagnoses being 2.65 (0.56). The ma-
jority of the AP-treated population had a primary or secondary di-
agnosis of an ASD (18), with ADHD being the second most common
primary or secondary diagnosis (19). Three participants met the
criteria for DBD diagnoses, including oppositional defiant disorder
(ODD, 2) and conduct disorder (CD, 1; Supplementary Fig. S1).
AP treatment varied but was inclusive of commonly used anti-
psychotic agents, and doses were consistent with typical pediatric
dosing: aripiprazole (n = 12, mean dose 9 – 6.4 mg); lurasidone (n = 1,
40 mg); olanzapine (n = 2, 12.5 – 10.6 mg); paliperidone (n = 1, 9 mg);
quetiapine (n = 4, 225 – 132.2 mg); risperidone (n = 4, 1.8 – 0.9 mg);
ziprasidone (n = 4, 5544.3 mg).
Session attendance was similar across treatment groups; the AP-
BWL group attended 10.26 (5.56) of 16 sessions (64%), the NP
group attended 11.91 (5.11) of 16 sessions (74%), and the monthly
RC group attended 3.14 (1.46) of 4 sessions (79%; F[2,44] = 0.92,
p = 0.41).
Primary and secondary outcomes
Whole-body adiposity. The mean change in DEXA-
measured total fat by treatment group can be seen in Table 1.
Significant differences in endpoint DEXA total fat, controlling for
baseline (F[2,34] = 4.81, p = 0.01), occurred across groups, ex-
plained by larger improvements observed in NP versus RC
( p = 0.03). Significant reductions from baseline in DEXA total fat
were observed for the NP group only (F[1,16] = 11.81, p = 0.003).
Screened
(N = 255)
Consented 
(n = 50)
Randomized to 
Treatment 
(n = 47)
Monthly Usual
Care
(n = 7)
Completers 
(n = 6)
Lost to follow-up (n = 41)
Excluded per protocol (n = 148)
Declined after screening (n = 16)
Lost to follow-up (n = 1)
Excluded per protocol (n = 1)
Withdrew consent (n = 1)
AP-treated BWL
(n = 19)
Non-psychiatric
BWL
(n = 21)
Completers
(n = 15)
Completers
(n = 17)
Lost to follow-up (n = 3)
Excluded (n = 1)
Withdrew consent (n = 0)
Lost to follow-up (n = 1)
Excluded (n = 0)
Withdrew consent  (n = 0)
Lost to follow-up (n = 4)
Excluded (n = 0)
Withdrew consent (n = 0)
FIG. 1. Participant disposition.
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Table 1. Baseline Participant Characteristics
AP-treated (n = 19) RC (n = 7) NP (n = 21)
Study population demographics
Age (in years), mean (SD) 13.35 (2.57) 12.80 (2.21) 13.42 (2.46)
0–11 Years of age, n (%) 8 (42.11) 2 (28.57) 6 (28.57)
12+ Years of age, n (%) 11 (57.89) 5 (71.43) 15 (71.43)
Female, n (%) 5 (26.32) 1 (14.29) 15 (71.43)
Nonwhite, n (%) 4 (21.05) 0 (100.00) 9 (42.86)
Concurrent stimulant use, n (%) 6 (31.58) 3 (42.86) 0 (0.00)
Primary outcomes, mean (SD)
DEXA total fat (kg) 32.40 (17.68) 31.94 (6.16) 35.97 (11.67)
PDFF (%) 6.52 (8.21) 12.01 (7.82) 4.72 (8.61)
CIMT (cm) 0.0451 (0.0074) 0.0494 (0.0058) 0.0504 (0.0065)
Psychiatric diagnoses, n (%)
Neurodevelopmental disordersa
Primary 11 (57.89) 5 (71.43) —
Secondary 1 (5.26) 1 (14.29) —
Tertiary 3 (15.79) 0 (0.00) —
ADHD
Primary 4 (21.05) 1 (14.29) —
Secondary 10 (52.63) 5 (71.43) —
Tertiary 1 (5.26) 0 (0.00) —
Mood disorderb
Primary 2 (10.53) 1 (14.29) —
Secondary 4 (21.05) 0 (0.00) —
Tertiary 3 (15.79) 0 (0.00) —
Disruptive behavior disorderc
Primary 0 (0.00) 0 (0.00) —
Secondary 0 (0.00) 0 (0.00) —
Tertiary 1 (5.26) 2 (28.57) —
PTSD
Primary 0 (0.00) 0 (0.00) —
Secondary 2 (10.53) 0 (0.00) —
Tertiary 0 (0.00) 0 (0.00) —
Anxiety disorderd
Primary 1 (5.26) 0 (0.00) —
Secondary 0 (0.00) 1 (14.29) —
Tertiary 2 (10.53) 2 (28.57) —
Tourette’s disorder
Primary 0 (0.00) 0 (0.00) —
Secondary 0 (0.00) 0 (0.00) —
Tertiary 0 (0.00) 1 (14.29) —
OCD
Primary 0 (0.00) 0 (0.00) —
Secondary 0 (0.00) 0 (0.00) —
Tertiary 1 (5.26) 0 (0.00) —
Psychotic disordere
Primary 1 (5.26) 0 (0.00) —
Secondary 2 (10.53) 0 (0.00) —
Tertiary 0 (0.00) 0 (0.00) —
aConsists of autism spectrum disorder, learning disabilities, and intellectual disabilities.
bConsists of major depressive disorder and bipolar disorder.
cConsists of conduct disorder and oppositional defiant disorder.
dConsists of generalized anxiety disorder, specific phobias, and panic disorder.
eConsists of schizophrenia and schizophreniform disorder.
ADHD, attention-deficit/hyperactivity disorder; AP-treated, antipsychotic-treated youth undergoing weekly weight loss treatment; CIMT, carotid
intima media thickness; DEXA, dual-energy X-ray absorptiometry; NP, nonpsychiatric youth undergoing weekly weight loss treatment; OCD, obsessive
compulsive disorder; PDFF, proton density fat fraction; PTSD, posttraumatic stress disorder; RC, antipsychotic-treated youth undergoing monthly
recommended care; SD, standard deviation.
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By contrast, BMI percentile, a clinical surrogate for body compo-
sition, decreased in all three treatment groups: -1.38 (2.09) in the
NP group, -1.92 (3.45) in the AP group, and -0.32 (0.70) in the RC
group (details are included in Supplementary Tables S1 and S2).
Hepatic fat content. Significant differences in endpoint
PDFF values were observed between groups (F[2,30] = 3.60,
p = 0.04), explained by larger beneficial changes in PDFF in NP-
BWL versus usual care (UC) youth ( p = 0.04) (Table 2). No sig-
nificant decreases in PDFF from baseline were detected in any
treatment group.
Carotid intima media thickness. No significant differences
in endpoint CIMT values were observed across groups, with no
consistent pattern of group-related change, and no detected sig-
nificant improvements from baseline in any group.
Exploratory analyses. A significant relationship was ob-
served between change in DEXA total fat and change in percent
PDFF (r = 0.49, p = 0.004) (Fig. 2). Treatment-related changes in
clinical variables and anthropomorphic measures are provided in
Supplementary Data. There was no main effect of time or treatment
group on adherence. No main effect of treatment group or adher-
ence was detected in a mixed model evaluating the main effect of
time on DEXA fat. Similarly, there was no main effect of time or
treatment group on fidelity. No main effect of treatment group or
fidelity was detected in a marginal model evaluating the main effect
of time on DEXA fat. The introduction of age group, stimulant use,
or gender into the primary model did not change the significance of
reported results.
Adverse events. The behavioral treatment was well toler-
ated, and no treatment-related adverse behavioral or medical events
were observed or reported.
Discussion
In this pilot randomized controlled trial, we set out to apply an
unadapted, evidence-based, BWL intervention for reducing total
body fat and associated markers of cardiometabolic risk. To our
knowledge, this is the first study to apply an evidence-based, in-
tensive, family-based, BWL intervention in AP-treated youth, us-
ing gold standard measures of cardiometabolic risk to evaluate
treatment effects. Greater improvements in total body fat and
hepatic fat were associated with BWL treatment of NP over-
weight/obese youth, relative to one or both comparison groups.
Both DEXA-measured fat and PDFF, which are proximal indi-
cators of risk for type 2 diabetes and hepatic steatosis, changed
differentially across treatment groups—namely, greater decreases
were observed in weekly treatment groups as opposed to the RC
group. While changes from baseline were statistically significant
only for DEXA fat change in the NP group, the clear attenuation
of what would otherwise be an ongoing fat gain in AP-treated
youth undergoing RC (e.g., nutritional and health behavior change
education) suggests possible utility of the intervention for attenu-
ation of ongoing fat gain.
In a prior cross-sectional study comparing chronically AP-
treated youth to age- and BMI percentile-matched NP youth, we
demonstrated that total body adiposity and liver fat were similar in
both treatment groups across a range of BMI percentile (Nicol et al.
2015), suggesting that total adiposity and associated cardiometa-
bolic risk (e.g., liver steatosis) can be explained by the BMI
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percentile achieved during treatment. Although not primary out-
comes of the present study, we detected numeric decreases in both
weight and BMI percentile in both weekly treatment groups. By
contrast, the RC group gained weight and had nominal change in
BMI percentile during the course of the study.
Reductions in total body and liver fat observed during weekly
treatment in NP youth were attenuated in AP-treated youth despite
similar session attendance. The tolerability of weekly treatment
was also similar in NP and AP-treated youth. This suggests that
factors other than treatment adherence, a previously reported pre-
dictor of short-term treatment response (Theim et al. 2013), might
contribute to greater effects on whole-body fat in NP versus AP-
treated youth. A large proportion of AP-treated youth in this study
were diagnosed with an ASD with prominent irritability, a condi-
tion for which certain antipsychotic treatments are approved. Prior
survey of parents of overweight/obese AP-treated children with
reported ASD indicated that difficulties changing health behaviors
were observed during previous efforts at weight loss treatment.
Specifically, aversion to physical activity and taste selectivity for
homogeneous and energy-dense foods commonly seen in children
with ASDs were reported as specific targets for treatment optimi-
zation (Nicol et al. 2016a). These and other challenges may offer
targets for further adaptation of BWL to optimize response in the
AP-treated population.
This pilot study is subject to limitations. First, our sample size
was small with numeric differences in variances across groups.
Furthermore, we included participants across a wide age range.
These factors together with the short length of treatment may have
reduced signal detection on primary outcomes, most specifically in
CIMT. Although correlated with obesity and cardiovascular dis-
ease in adults (Koskinen et al. 2014), CIMT may be less sensitive in
children than biomarkers such as PDFF (Nicol et al. 2015). In
addition, substantial weight loss over 6–12 months may be required
to demonstrate change in this marker of risk (Wunsch et al. 2006).
Finally, our CIMT measurement method used the use of far-wall
measurement only, which likely impacted the precision and re-
producibility of the results. Finally, while changes in physical ac-
tivity and dietary content were a primary focus of the BWL
treatment used, these variables were not formally measured in this
pilot study. Together, these factors may limit the interpretation of
our findings.
Conclusion
Overall, the results confirm that BWL interventions can favor-
ably impact early measures of cardiometabolic risk in youth. Ef-
fects were attenuated in the high-risk population of AP-treated
youth, which may be attributed to unique behavioral characteristics
and needs (Nicol et al. 2016a). Youth with AP-induced obesity may
benefit from unadapted BWL interventions. However, treatment
modifications may be needed to optimize results in the challenging
population of AP-treated youth. Future targeted adaptation efforts
will be needed to maximize effectiveness in these individuals.
Clinical Trials Registration: NCT01222494.
Clinical Significance
These results should be interpreted with caution. While
antipsychotic-treated youth demonstrated weight attenuation and
modest metabolic benefit from an intensive BWL intervention,
future studies testing optimized BWL interventions in this and
other vulnerable populations are needed to determine how best to
maximize treatment efficacy in high-risk youth.
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